Posts Tagged ‘Metastatic’

Additional Data on Provectus’s PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences

Additional Data on Provectus’s PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.

Read more on Business Wire

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer
Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

Read more on News-Medical-Net

Metastatic Breast Cancer Stories

Conn Jackson interviews Fern Saitowitz, a woman diagnosed with Breast Cancer, and Dr. Anne Coscarelli about Metastatic Breast Cancer, which is stage 4 cancer. Fern tells her story about her diagnosis and the two women share their message that these women are not alone in their struggles.

Plexxikon’s PLX4032 shows positive data in patients with metastatic melanoma

Plexxikon’s PLX4032 shows positive data in patients with metastatic melanoma
Plexxikon today announced positive preliminary data from a pivotal Phase 2 clinical trial of PLX4032 (RG7204) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients.

Read more on News-Medical-Net

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer
Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for …

Read more on News-Medical-Net

Edmonton metastatic cancer patient says she’s running out of treatment options

Edmonton metastatic cancer patient says she’s running out of treatment options
Edmonton’s Daria Maluta is working with the Canadian Breast Cancer Network (CBCN) to raise awareness about metastatic breast cancer, an advanced, late-stage breast cancer that she’s been living with for the past 2 years.[...]

Read more on The Edmonton Examiner

FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR …

FDA Approves New Dosing for FASLODEX® (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR …
WILMINGTON, Del., Sept. 10 /PRNewswire-FirstCall/ — AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following …

Read more on redOrbit

Metastatic Breast Cancer in Pleural Fluid

Image taken on 2008-02-25 12:50:28 by euthman.

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress
Keryx Biopharmaceuticals, Inc. today announced that abstract O-0017, entitled “Subset Analysis of 5-FU Refractory Patients from a Randomized Ph II Study of Perifosine + Capecitabine (P-CAP) vs. Placebo + Capecitabine (CAP) in Patients with 2nd or 3rd Line Metastatic CRC” has been selected for oral presentation at the upcoming 12th World Congress on Gastrointestinal Cancer, to be held in …

Read more on News-Medical-Net

Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer

Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer
read more

Read more on SYS-CON Media